Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Add as a preferred source on Google
RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2018 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its fourth quarter and full year 2017 financial results will be reported on Tuesday, February 27, 2018.
BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss financial results and to provide an update regarding the Company's clinical development programs. The call will be led by Jon P. Stonehouse, President & Chief Executive Officer, Thomas R. Staab II, Senior Vice President & Chief Financial Officer, and Dr. Bill Sheridan, Senior Vice President and Chief Medical Officer.
Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule medicines that address both common and rare conditions. BioCryst has several ongoing development programs including BCX7353, an oral treatment for hereditary angioedema, galidesivir, a potential treatment for filoviruses, and a preclinical program to develop oral Alk-2 inhibitors for the treatment of fibrodysplasia ossificans progressive (FOP). RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at https://biocryst.gcs-web.com/financial-information/sec-filings.
BCRXW
CONTACT: Thomas Staab, BioCryst Pharmaceuticals, +1-919-859-7910
